Interestingly, hepAGT+/+ mouse-derived serum stimulation exacerbated hepatocyte steatosis in vitro (supplemental Fig. S8) and was associated with the Akt/mTOR pathway and subsequently promoted SREBP-1c expression, which could be diminished by treating with MK2206, an Akt inhibitor, and rapamycin, a mTOR inhibitor, respectively (Fig. 5). Here, SREBF1 is linked to steatosis.